Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: a case-control study
- 20 July 2018
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 27 (12), 1903-1910
- https://doi.org/10.1177/0961203318787035
Abstract
Preterm delivery for preeclampsia or placental insufficiency (PREPI) is a clinical criterion for antiphospholipid syndrome (APS), but no prior prospective studies have used the international classification criteria for APS. Our objective is to determine the proportion of women with PREPI who test positive for aPL using international criteria for antiphospholipid antibody (aPL) assays. We conducted a prospective, case-control study of 148 women delivered < 36 weeks because of PREPI compared to 148 controls. PREPI cases delivered < 36 weeks were compared to matched controls. Cases and controls were tested for aPL. Demographic variables were compared with chi-squared and Wilcoxon-rank-sum statistics. Rates of + aPL were compared using adjusted odds ratios (aORs) for maternal body mass index (BMI) and Caucasian race. Positive aPL (+aPL) was defined as lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin G (IgG) (GPL) or immunoglobulin M (IgM) (MPL) ≥ 40, or anti-β2-glycoprotein I (aβ2GPI) IgG (SGU) or IgM (SMU) ≥ 40. Controls were more likely to be Caucasian (87% vs 70%, p = 0.006) and had lower BMIs (BMI 26 vs 33, p < 0.001). Positive aPL were found more commonly in cases than controls (11.5% vs 1.4%, aOR 8.9 (95% CI 1.9–41.4)). In + aPL cases, 76% had + LA, 41% had + aCL, and 24% had + aβ2GPI. Women requiring early delivery for PREPI are more likely to have aPL (and thus APS) than controls. This is the first prospective study using both obstetric definitions and laboratory criteria in accordance with APS international criteria.Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (1K12HD085816)
This publication has 46 references indexed in Scilit:
- Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal lossThe Journal of Pathology, 2011
- Observational study of pregnant women with a previous spontaneous abortion before the 10th gestation week with and without antiphospholipid antibodiesJournal of Thrombosis and Haemostasis, 2010
- Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory moleculeLupus, 2008
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2008
- Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodiesAmerican Journal of Obstetrics and Gynecology, 2007
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Thrombophilia Is Significantly Associated With Severe PreeclampsiaHypertension, 2005
- Anticardiolipin and Anti-β2-Glycoprotein-I Antibodies in Hypertensive Disorders of PregnancyArchives of Medical Research, 2002
- Antiphospholipid Antibodies in Patients With PreeclampsiaAmerican Journal of Reproductive Immunology, 1996
- Lupus anticoagulant and anticardiolipin antibodies in an obstetric populationActa Obstetricia et Gynecologica Scandinavica, 1992